131
2
1
11
Cat. No. | Product Name | ||
---|---|---|---|
L2191 | 抗乳腺癌化合物库 | 1939 compounds | |
1939 种与乳腺癌相关的化合物,可以用于抗乳腺癌药物研发和药理研究; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10736 |
CDK4/6-IN-2
|
CDK | Cell Cycle/Checkpoint |
CDK4/6-IN-2 是一种CDK4和CDK6抑制剂,IC50分别为 2.7 和 16 nM。 | |||
T39957 |
CDK4/6-IN-6
|
CDK | Cell Cycle/Checkpoint |
CDK4/6-IN-6 是CDK4/CDK6的有效抑制剂,结合CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 为 0.6 nM 和 13.9 nM。 | |||
T10735 |
CDK4/6/1 Inhibitor
Crozbaciclib |
CDK | Cell Cycle/Checkpoint |
CDK4/6/1 Inhibitor (Crozbaciclib) 是一种 CDK4/6 抑制剂 (IC50s: 3 and 1 nM). CDK4/6抑制剂是一类用于治疗一些类型的激素受体阳性、her2阴性乳腺癌的化合物,可阻断了乳腺癌细胞分裂和繁殖的过程。 | |||
T39956 |
CDK4/6-IN-5
CDK4/6-IN-5 |
||
CDK4/6-IN-5 is a highly effective inhibitor of CDK4 and CDK6, with Ki values of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively (WO2019207463A1, example A93). | |||
T21720 |
GP-82996
Cdk4/6 Inhibitor IV,CINK4 |
CDK | Cell Cycle/Checkpoint |
GP-82996 (CINK4) (CINK4) 是 CDK4/6的药理学抑制剂。GP-82996 对 CDK4/cyclin D1、CDK6/cyclin D1 和 Cdk5/p35 的 IC50s 分别为 1.5、5.6 和 25 μM。GP-82996 诱导肿瘤细胞 U2OS 的凋亡,可用于癌症研究。 | |||
T2381 |
Abemaciclib
CDK4/6 dual inhibitor,LY2835219 |
CDK | Cell Cycle/Checkpoint |
Abemaciclib (LY2835219) 是一种 CDK4/6 的双重抑制剂 (IC50=2/10 nM),具有选择性和特异性。Abemaciclib 具有抗肿瘤活性,被用于治疗晚期或转移性乳腺癌。 | |||
T10738 |
Abemaciclib metabolite M20
CDK4/6-IN-4,LSN3106726 |
CDK | Cell Cycle/Checkpoint |
Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂,可用于癌症治疗的相关研究。 | |||
T2082 |
CDK4-IN-1
|
CDK | Cell Cycle/Checkpoint |
CDK4-IN-1 是一种新型的特异性 CDK4/Cyclin D1 抑制剂,IC50 为 10 nM;分别是 CDK1/Cyclin B (IC50>15 uM) 和 CDK2/Cyclin A (IC50=5.265 uM) 的 1500 倍和 500 倍。 | |||
T10737 |
CDK4/6-IN-3
|
CDK | Cell Cycle/Checkpoint |
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM. | |||
T67780 |
AM5992
CDK4/6-IN-16 |
CDK | Cell Cycle/Checkpoint |
AM5992 (化合物195) 是有效的CDK4和CDK6抑制剂(CDK4,IC50=0.013μM)。AM5992可用于CDK4介导的疾病的研究。 | |||
T60328 | CDK4/6-IN-12 | ||
CDK4/6-IN-12 是一种有效的细胞周期蛋白依赖性激酶 4/6 抑制剂。CDK4/6-IN-12 对 CDK4 和 CDK6 具有抑制活性,IC50值分别为 592.3 nM 和 3090 nM。 CDK4/6-IN-12 可用于癌症的研究。 | |||
T74370 |
CDK4/6-IN-11
|
||
CDK4/6-IN-11 是一种有效的PROTACCDK4/6降解剂。 | |||
T72951 |
CDK4/6-IN-14
|
||
CDK4/6-IN-14 是一种有效且高度选择性的 CDK4和 CDK6(CDK) 抑制剂,IC50分别为 10 nM 和 16 nM。CDK4/6-IN-14 的选择性是 CDK1、2、7 和 9 的 60 多倍,并且在其他 205 种激酶中表现出高选择性。 | |||
T64244 | CDK4/6-IN-10 | ||
CDK4/6-IN-10 是一种选择性的、有效的、口服具有活力的 CDK4 (IC50: 22 nM) 和 CDK6 (IC50: 10 nM) 抑制剂,具有抗肿瘤效果。CDK4/6-IN-10 具有潜力进行多发性骨髓瘤 (MM) 的研究。 | |||
T79112 |
CDK4/6-IN-17
|
CDK | Cell Cycle/Checkpoint |
CDK4/6-IN-17(compound 12)为具有口服活性的CDK4/6抑制剂,在BE(2)细胞的IC50为10-100 nM。CDK4/6-IN-17在COLO205异种移植模型中有效抑制肿瘤生长。 | |||
T61738 | CDK4/6-IN-7 | ||
CDK4/6-IN-7, a highly potent and selective orally active inhibitor of CDK4/6, demonstrates impressive inhibition activity with IC50 values of 1.58 nM and 4.09 nM respectively. This compound is particularly valuable for breast cancer research [1]. | |||
T61892 |
CDK4/6-IN-8
|
||
CDK4/6-IN-8 (Compound 7p) 是选择性的CDK4(IC50= 5.01 nM)和CDK6(IC50= 3.97 nM)抑制剂。 | |||
T62192 |
CDK4/6-IN-9
|
||
CDK4/6-IN-9 (compound 10) 是一种 CDK4/6 的选择性抑制剂,能够作用于 CDK6/cyclin D1 (IC50: 905 nM)。CDK4/6-IN-9 对多发性骨髓瘤 (MM) 具有潜在的研究价值。 | |||
T62605 |
CDK4/6-IN-13
|
||
作为CDK4/6抑制剂。化合物10b 和10c 在CDK4/6上表现出低纳摩尔范围的活性,理想的抗增殖活性,优异的代谢性质和可接受的药代动力学特性。 | |||
T72928 |
CDK4/6-IN-15
|
||
CDK4/6-IN-15 是一种口服有效和选择性 CDK4/6抑制剂。CDK4/6-IN-15 能有效抑制癌细胞生长。CDK4/6-IN-15 将细胞周期阻滞在 G1 期,并抑制视网膜母细胞瘤肿瘤抑制蛋白 (Rb) 在 S780 位点的磷酸化和 E2 因子 (E2F) 调控的基因表达。 | |||
T79046 |
CDK4-IN-2
|
CDK | Cell Cycle/Checkpoint |
CDK4-IN-2 (A17) 作为CDK4的抑制剂,其对应的Ki和 IC50值均不超过 10 nM。 | |||
T9628 |
10074-A4
|
c-Myc | Cell Cycle/Checkpoint |
10074-A4 是与 c-Myc370-409 结合的 c-Myc 结合化合物,具有抗癌作用,其行为类似于“蛋白质云”周围的“配体云”,具有与非结合配体不同的特征。 | |||
T75029 | HEMTAC CDK4/6 degrader 1 | ||
HEMTAC CDK4/6 degrader 1 是一种通过连接HSP90的配体和CDK4/6而形成的PROTAC,其Kd值为35.7 µM。在B16F10黑色素瘤细胞中,该化合物能够诱导CDK4/6的降解,从而将细胞周期阻滞在G0/G1期,并引发细胞凋亡。因此,HEMTAC CDK4/6 degrader 1可被应用于癌症研究领域。 | |||
T63135 | FLT3/CDK4-IN-1 | ||
FLT3/CDK4-IN-1 是一种高度选择性的、有效的、口服具有活力的 FLT3/CDK4 双重抑制剂,作用于 FLT3 (IC50: 7 nM) 与 CDK4 (IC50: 11 nM)。FLT3/CDK4-IN-1 在体内具有良好的抗肿瘤效果,对某些癌细胞表现出抗增殖作用。 | |||
T72836 |
SHP2/CDK4-IN-1
|
||
SHP2/CDK4-IN-1(化合物10)是一种针对SHP2和CDK4的口服双重抑制剂,具有IC50值分别为4.3和18.2 nM。该化合物能有效引起G0/G1期阻滞,抑制TNBC细胞的增殖,并在EMT6同源小鼠模型中展现出明显的抗肿瘤活性,适用于三阴性乳腺癌(TNBC)的研究。 | |||
T8762 |
SW106065
SW-106065 |
Apoptosis | Apoptosis |
SW106065 是一种恶性外周神经鞘瘤(MPNST)细胞凋亡诱导剂。 它抑制 sMPNST 和其他 MPNST 模型的 ATP 消耗,EC50 为 1 µM。 | |||
T36694 |
XY028-140
XY028-140 |
CDK; Ligand for E3 Ligase; PROTACs | Cell Cycle/Checkpoint; PROTAC |
XY028-140 是一种特异性 CDK4/CDK6 降解,抑制 CDK4/6 在癌细胞中的表达和活性。 XY028-140 是一种 PROTAC,由 Cereblon 配体和 CDK 配体相连接。 | |||
T6920 |
ON123300
|
FGFR; c-RET; JAK; CDK; PDGFR; Src; AMPK | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
ON123300 是一种可透过血脑屏障的多激酶抑制剂,作用于 CDK4、CDK6、Ark5、PDGFRβ、FGFR1、RET 和 Fyn,IC50值为3.9、9.82、5、26、26、9.2和11 nM。它在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。 | |||
T13202 |
Trilaciclib hydrochloride
G1T28 hydrochloride |
CDK | Cell Cycle/Checkpoint |
Trilaciclib hydrochloride (G1T28 hydrochloride) 是一种CDK4/6的抑制剂,对 CDK4 和 CDK6 的IC50值分别为 1 nM 和 4 nM。 | |||
T3111 |
Abemaciclib methanesulfonate
abemaciclib mesylate,LY2835219,LY2835219 mesylate,LY2835219 (methanesulfonate) |
CDK | Cell Cycle/Checkpoint |
Abemaciclib methanesulfonate (LY2835219) 是一种选择性的CDK4/6抑制剂,能够抑制 CDK4/CDK6 的活性,IC50分别为 2 nM 和 10 nM。 | |||
T6756 |
AMG 925
|
FLT; CDK | Angiogenesis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
AMG 925 是一种选择性FLT3/CDK4双重抑制剂,IC50分别为 1 nM 和 3 nM。 | |||
T11345L |
Lerociclib dihydrochloride
G1T38 dihydrochloride |
CDK | Cell Cycle/Checkpoint |
Lerociclib dihydrochloride (G1T38 dihydrochloride) 是一种有效的选择性CDK4/CDK6抑制剂,抑制CDK6/CyclinD3和CDK4/CyclinD1,IC50值分别为 2 nM 和 1 nM。 | |||
T6924 |
Riviciclib hydrochloride
P276-00 |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
Riviciclib hydrochloride (P276-00) 是一种CDK 抑制剂,抑制CDK9-cyclinT1、CDK4-cyclin D1、CDK1-cyclinB 的IC50值分别为 20 nM、63 nM、79 nM。它对 Cisplatin 耐药性细胞具有抗肿瘤活性。 | |||
T15732 |
Ribociclib succinate
LEE011 琥珀酸盐,瑞博西尼琥珀酸盐,LEE011 succinate |
CDK | Cell Cycle/Checkpoint |
Ribociclib succinate (LEE011 succinate) 是一种高度特异性的CDK4/6抑制剂,IC50值分别为 10 nM 和 39 nM。它对细胞周期蛋白 B/CDK1 复合物的效力低 1000 倍。 | |||
T2059 |
Purvalanol A
NG-60 |
Apoptosis; CDK; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint |
Purvalanol A (NG-60) 是一种CDK 抑制剂,对 cdc2-cyclin B、cdc2-cyclin B、cdk2-cyclin E、cdk4-cyclin D1 和 cdk5-p35 的IC50值分别为 4、70、35、850 和 75 nM。 | |||
T23284 |
Ryuvidine
|
Histone Demethylase; Histone Methyltransferase; CDK | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Ryuvidine 是一种 KDM5A 和 SETD8 双重抑制剂,是一种 DNA 损伤反应的诱导剂,具有潜在的抗癌活性,抑制 H4K20 甲基化,抑制 CDK4,可用于研究乳腺癌和红斑病。 | |||
T10220 |
LSN2839567
Abemaciclib metabolite M2 |
CDK | Cell Cycle/Checkpoint |
LSN2839567 (Abemaciclib metabolite M2) 是 Abemaciclib 的活性代谢物,是一种强效的 CDK4 和 CDK6 抑制剂(IC50s:1-3 nM),具有抗癌活性。LSN2839567 抑制 CDK9。LSN2839567 以浓度依赖性方式抑制细胞生长和细胞周期进程,可用于研究乳腺癌和肺癌。 | |||
T6167 |
SU9516
|
Apoptosis; p38 MAPK; CDK; PKC; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK |
SU9516 是一种 CDK2抑制剂,IC50值为 22 nM,对 CDK1 和 CDK4 也有抑制作用,IC50值分别为 40 和 200 nM。 | |||
T6240 |
Palbociclib Isethionate
Palbociclib (PD0332991) Isethionate,帕博西尼羟乙基磺酸盐,PD 0332991 isethionate,帕布昔利布羟乙基磺酸盐 |
CDK | Cell Cycle/Checkpoint |
Palbociclib Isethionate (PD 0332991 isethionate) 是一种高选择性的CDK4/6抑制剂,IC50为11 nM 和16 nM。它对一组 36 种额外的蛋白激酶没有抑制作用。 | |||
T60098 |
MSC2504877
3-(4-(2-Hydroxypropan-2-yl)phenyl)-6-methylpyrrolo[1,2-a]pyrazin-1(2H)-one |
Others | Others |
MSC2504877 是一种tankyrase 抑制剂,可增强临床CDK4/6 抑制剂的作用。 MSC2504877 抑制由 palbociclib 引起的 Cyclin D2 和 Cyclin E2 的上调,并增强对 phospho-Rb 的抑制。 | |||
T15335 |
FN-1501
|
FLT; CDK | Angiogenesis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
FN-1501 是一种有效的 FLT3 和 CDK 抑制剂,具有抗肿瘤的活性,对 CDK2/cyclin A、CDK4/cyclin D1、CDK6/cyclin D1 和 FLT3 的 IC50值分别为 2.47、0.85、1.96 和 0.28 nM。 | |||
T1785 |
Palbociclib
PD 0332991,帕博西尼,帕布昔利布 |
CDK | Cell Cycle/Checkpoint |
Palbociclib (PD 0332991) 是一种 CDK 抑制剂,抑制 CDK4 和 CDK6 (IC50=11/16 nM),具有口服活性。Palbociclib 具有抗肿瘤活性,有用于 ER 阳性和 HER2 阴性乳腺癌的研究潜力。 | |||
T8463 |
PF-06873600
|
CDK | Cell Cycle/Checkpoint |
PF-06873600 是一种选择性和口服生物可利用的细胞周期蛋白依赖性激酶 (CDK) 抑制剂(CDK2、CDK4 和 CDK6,Ki 分别为 0.09 nM、0.13 nM 和 0.16 nM),具有潜在的抗肿瘤活性。 | |||
T6837 |
Flavopiridol
L868275,Alvocidib,夫拉平度,NSC 649890 HCl,HMR-1275 |
Apoptosis; HIV Protease; CDK; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; Microbiology/Virology; Proteases/Proteasome |
Flavopiridol (Alvocidib) 是一种广谱CDK 竞争型抑制剂, 抑制 CDK1,CDK2,CDK4的IC50分别为30,170,100 nM。 | |||
T6239 |
Palbociclib monohydrochloride
PD 0332991 hydrochloride,Palbociclib hydrochloride,帕布昔利布盐酸盐,Palbociclib (PD-0332991) HCl |
CDK | Cell Cycle/Checkpoint |
Palbociclib monohydrochloride (PD 0332991 hydrochloride) 是一种口服的细胞周期蛋白依赖性激酶 (CDK) 抑制剂,具有潜在的抗肿瘤活性。它抑制 CDK4和 CDK6,IC50分别为11 nM,16 nM。它有用于 ER 阳性和 HER2 阴性乳腺癌的研究潜力。 | |||
T28218 |
NU6102
NU-6102,NU 6102 |
CDK | Cell Cycle/Checkpoint |
NU6102 是一种具有选择性和有效性的 ATP 竞争性 CDK2 抑制剂,具有抗肿瘤活性,对 CDK1/cyclinB、CDK2/cyclinA3、CDK1/CDK2、 CDK4、DYRK1A 、PDK1、ROCKII 具有抑制作用,可用于研究直肠癌。 | |||
T9636 |
Dalpiciclib
SHR-6390 |
CDK | Cell Cycle/Checkpoint |
Dalpiciclib (SHR-6390) 是一种高选择性、口服生物利用度和相当效力的 CDK4 和 CKD6 抑制剂,IC50 分别为 12.4 nM 和 9.9 nM。它通过抑制磷酸化 Rb 蛋白和诱导 G1 细胞周期阻滞在食管鳞状细胞癌中发挥有效的抗肿瘤活性。 | |||
T13361 |
XY028-133
|
CDK; PROTACs | Cell Cycle/Checkpoint; PROTAC |
XY028-133 是一种基于 PROTAC 的 CDK4/6 降解剂,可用于研究肿瘤。 | |||
T6199 |
Ribociclib
瑞博西尼,LEE011 |
VEGFR; CDK | Angiogenesis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
Ribociclib (LEE011) 是一种口服有效的高特异性 CDK4/6 抑制剂,IC50值分别为 10 nM 和 39 nM。 | |||
T61722 |
ZDLD20
|
Apoptosis | Apoptosis |
ZDLD20 是一种具有口服活性和选择性的CDK4抑制剂,是一种 β-咔啉类化合物,具有抗 HCT116 和抗癌活性,抑制集落形成、抑制侵袭和迁移、诱导细胞凋亡和阻止细胞周期的 G1 期。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16324 |
Nimbolide
|
Apoptosis; NF-κB; CDK | Apoptosis; Cell Cycle/Checkpoint; NF-κB |
Nimbolide 是源自印楝叶和花的一种三萜。它抑制CDK4/CDK6激酶活性。它抑制 NF-κB,Wnt,PI3K-Akt,MAPK 和 JAK-STAT 信号通路。它通过抑制NF-κB 而诱导肿瘤细胞凋亡。 | |||
TN1664 |
Ganoderic acid H
|
NF-κB; DNA/RNA Synthesis; CDK | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; NF-κB |
Ganoderic acid H 是一种羊毛脂烷型三萜,提取自灵芝中。它能够抑制转录因子AP-1 和 NF-kappaB 信号,并抑制乳腺癌细胞细胞的生长和入侵。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04548 |
CDK4 Protein, Human, Recombinant (GST)
CMM3,PSK-J3,cyclin-dependent kinase 4 |
Human | Baculovirus Insect Cells |
CDK4 is a member of the Ser/Thr protein kinase family. It is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of CDK4 is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). CDK4 was shown to be responsible for the phosphorylation of retinoblastoma gene product. CDK4 is the ser... | |||
TMPH-01169 |
CDK4 Protein, Human, Recombinant (His)
Cyclin-dependent kinase 4,CDK4,Ce... |
Human | E. coli |
CDK4 Protein, Human, Recombinant (His) is expressed in E. coli. | |||
TMPY-02495 |
p19 INK4d Protein, Human, Recombinant (GST)
p19-INK4D,INK4D,cyclin-dependent kinase in... |
Human | E. coli |
Cyclin-dependent kinase inhibitor 2D(also known as CDKN2D or p19ink4d), a member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors, negatively regulates the cyclin D-CDK4/6 complexes, which promote G1/S transition by phosphorylating the retinoblastoma tumor-suppressor gene product. It is clearly shown that DNA repair is the main target of p19ink4d effect and that diminished apoptosis is a downstream event. Experiments has uncovered a role of p19INK4d as a regulator of DNA-damage-ind... | |||
TMPJ-00972 |
CDKN1B Protein, Human, Recombinant (His)
KIP1,CDKN1B,Cyclin-Dependent Kinase Inhibitor p27,C... |
Human | E. coli |
Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B) is a Kinesin-related motor protein necessary for mitotic spindle assembly and chromosome segregation. CDKN1B is expressed in all tissues with highest levels observed in skeletal muscle. CDKN1B is a potent inhibitor of Cyclin E- and Cyclin A-CDK2 complexes. CDKN1B forms a complex with Cyclin Type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. In addition, CDKN1B acts as an inhibitor or an ... | |||
TMPJ-00936 |
CCND2 Protein, Human, Recombinant (His)
G1/S-specific cyclin-D2,CCND2 |
Human | E. coli |
CCND2,also known as G1/S-specific cyclin-D2,is a member of the highly conserved cyclin family. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. Cyclins function as regulators of CDK kinases. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. CCND2 is involved in a number of fundamental biological processes such ... | |||
TMPJ-00963 |
CDKN2C Protein, Human, Recombinant (His)
Cyclin-Dependent Kinase 4 Inhibitor C,p18-INK4<... |
Human | E. coli |
Cyclin-Dependent Kinase 4 Inhibitor C (CDKN2C) is a member of the INK4 family of cyclin dependent kinase inhibitors. CDKN2C contains 4 ANK repeats and interacts with CDK4 or CDK6. Highest levels of CDKN2C can be found in skeletal muscle, pancreas, and heart. CDKN2C inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB and prevent the activation of the CDK kinases. Studies have been shown the roles of CDKN2C gene in regulating spermatogenesis,... | |||
TMPJ-00703 |
Gankyrin Protein, Human, Recombinant
PSMD10,Gankyrin,26S Proteasome Non-ATPase Regulatory Subunit... |
Human | E. coli |
Gankyrin is a multicatalytic proteinase oncoprotein consists of 7 ankyrin repeats. Gankyrin overexpressed in most hepatocellular carcinomas. Gankyrin is involved in theregulation of the phosphorylation of the retinoblastoma protein by CDK4 to enhance the ubiquitinylation of p53 by MDM2. Gankyrin is also involved in progression of esophageal squamous cell carcinoma. Gankyrin plays an oncogenic role especially in early stages of human epatocarcinogenesis. | |||
TMPY-04542 |
CDK2 Protein, Human, Recombinant (His)
CDKN2,cyclin-dependent kinase 2,p33(CDK2) |
Human | Baculovirus Insect Cells |
CDK2 is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2. It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. Cdks (cyclin-dependent kinases) are heteromeric serine/threonine kinases that control progression through the cell cycle in concert with their regulatory subunits, the c... | |||
TMPY-03599 |
RPRD1B Protein, Human, Recombinant (His)
C20orf77,regulation of nuclear pre-mRNA domain containing 1B... |
Human | HEK293 Cells |
RPRD1B, together with RPRD1A, can accompany RNAP II from promoter regions to 3'-untranslated regions during transcription in vivo, predominantly interact with phosphorylated RNAP II, and can reduce CTD S5- and S7-phosphorylated RNAP II at target gene promoters. RNA polymerase II C-terminal domain (CTD) phosphorylation is important for various transcription-related processes. RPRD1B is a transcriptional regulator that enhances expression of CCND1. It also enhances the transcription of a number of... | |||
TMPH-02613 |
ATF-5 Protein, Mouse, Recombinant (His & Myc)
Transcription factor ATFx,Transcription factor-like protein ... |
Mouse | E. coli |
Transcription factor that either stimulates or represses gene transcription through binding of different DNA regulatory elements such as cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), ATF5-specific response element (ARE) (consensus: 5'-C[CT]TCT[CT]CCTT[AT]-3') but also the amino acid response element (AARE), present in many viral and cellular promoters. Critically involved, often in a cell type-dependent manner, in cell survival, proliferation, and differentiation. Its transcrip... | |||
TMPH-01552 |
IRF1 Protein, Human, Recombinant (GST & His)
|
Human | Baculovirus Insect Cells |
Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses. Regulates transcription of IFN and IFN-inducible genes, host response to viral and bacterial infections, regulation of many genes expressed during hematopoiesis, inflammation, immune responses and cell proliferation and differentiation, regulation of the cell cycle and induction of growth arrest and programmed cell death following DNA damage. Stimulates both innate and acquired imm... |